EA201201198A2 - METHOD OF BRAKING GROWTH OF ELF CARCINOMA IN THE LABORATORY ANIMAL - Google Patents
METHOD OF BRAKING GROWTH OF ELF CARCINOMA IN THE LABORATORY ANIMALInfo
- Publication number
- EA201201198A2 EA201201198A2 EA201201198A EA201201198A EA201201198A2 EA 201201198 A2 EA201201198 A2 EA 201201198A2 EA 201201198 A EA201201198 A EA 201201198A EA 201201198 A EA201201198 A EA 201201198A EA 201201198 A2 EA201201198 A2 EA 201201198A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- laboratory animal
- carcinoma
- elf
- braking
- growth
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к медицине и биологии, к области экспериментальной онкологии и позволяет добиться торможения роста перевиваемой карциномы Эрлиха у лабораторного животного за счет внутрибрюшинного введения не обладающего повреждающим действием в отношении ДНК и мембран клеток водного раствора фактора роста нервов, полученного из змеиного яда.The invention relates to medicine and biology, to the field of experimental oncology and allows you to achieve growth inhibition of transplantable Ehrlich carcinoma in a laboratory animal due to intraperitoneal administration of an aqueous solution of nerve growth factor derived from snake venom without damaging effect on DNA and cell membranes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BY20111262 | 2011-09-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201201198A2 true EA201201198A2 (en) | 2013-03-29 |
EA201201198A3 EA201201198A3 (en) | 2013-07-30 |
EA022546B1 EA022546B1 (en) | 2016-01-29 |
Family
ID=47988444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201198A EA022546B1 (en) | 2011-09-28 | 2012-09-27 | Method for inhibiting growth of ehrlich carcinoma in laboratory animal |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA022546B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2774589C1 (en) * | 2021-10-30 | 2022-06-21 | Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ радиологии» Минздрава России) | Method for carrying out photodynamic therapy of solid ehrlich carcinoma in mice |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5630997A (en) * | 1979-08-24 | 1981-03-28 | Toyama Chem Co Ltd | Carcinostatic substance tf-120, its preparation, and carcinostatic comprizing it |
CN100589839C (en) * | 2003-01-28 | 2010-02-17 | 艾恩伍德医药品股份有限公司 | Polypeptide and medicament composition containing polypeptide |
EA011866B1 (en) * | 2004-10-19 | 2009-06-30 | Амджен Инк. | Angiopoetin-2 specific binding agents |
-
2012
- 2012-09-27 EA EA201201198A patent/EA022546B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2774589C1 (en) * | 2021-10-30 | 2022-06-21 | Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ радиологии» Минздрава России) | Method for carrying out photodynamic therapy of solid ehrlich carcinoma in mice |
Also Published As
Publication number | Publication date |
---|---|
EA201201198A3 (en) | 2013-07-30 |
EA022546B1 (en) | 2016-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN01300A (en) | ||
EA201991369A1 (en) | MODIFIED RNA GUIDES | |
EA201391019A1 (en) | CONNECTIONS AND METHODS FOR KINAZ MODULATION AND ALSO THE INDICATIONS TO THEIR APPLICATION | |
MX2016007541A (en) | Modified nucleic acid molecules and uses thereof. | |
EA201500207A1 (en) | HETEROAROMATIC COMPOUNDS AS VTK INHIBITORS | |
EA201401281A1 (en) | D-AMINO ACID CHEMICAL COMPOUNDS FOR THE TREATMENT OF LIVER DISEASES | |
SG10201906673WA (en) | Artificial nucleic acid molecules | |
CY1117858T1 (en) | Oligonucleotides for the induction of a change in the sequence of a molecule-target RNA present in a living cell | |
DK3115457T3 (en) | PROCEDURE FOR MODIFYING GENE SEQUENCE TO SPECIFICALLY CONVERT THE NUCLEIC ACID BASES OF TARGETED DNA SEQUENCE AND MOLECULAR COMPLEX TO USE IN SAME | |
EP3340925A4 (en) | Blood pump controllers and methods of use for improved energy efficiency | |
BR112015016136A2 (en) | methods to isolate microvesicles | |
DK3311827T3 (en) | NANOPARTICLES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF AS CARRIERS FOR AMPHIPATHIC OR HYDROPHOBIC MOLECULES IN THE MEDICAL FIELD, INCLUDING CANCER TREATMENT, AS WELL AS FOOD-RELATED COMPOUNDS | |
EP3161160A4 (en) | Methods of analyzing nucleic acids from individual cells or cell populations | |
TR201901939T4 (en) | Antisense nucleic acid. | |
SG10201710631RA (en) | Artificial nucleic acid molecules for improved protein or peptide expression | |
AR093377A1 (en) | ANTI-NOTCH ANTIBODIES AND ANTIBODY-FARMACO CONJUGATES | |
EA201690529A1 (en) | METHODS OF MODIFICATION OF CELL-HOST | |
BR112013018898A2 (en) | treatment of autism spectrum disorders employing glycyl-1-2-methylprolyl-1-glutamic acid. | |
EP3368178A4 (en) | Methods and systems for controlling dna, rna and other biological molecules passing through nanopores | |
DK3036320T3 (en) | MANAGEMENT OF PROTEIN GLYCOSYLATION BY CULTIVATION MEDIA ADDITION AND CELL CULTURE PROCESS PARAMETERS | |
EA201301336A1 (en) | TREATMENT OF CANCER BY THE COMBINATION OF DNA MOLECULES THINKING TWO-DEPLOYMENT DISTRIBUTIONS AND HYPERTHERMIA | |
IN2015DN02479A (en) | ||
EP2569014A4 (en) | Treatment methods | |
UY34371A (en) | NUCLEIC ACID MOLECULES THAT ARE ADDRESSED TO RPS6 AND CONFERENCE RESISTANCE TO PATHOPHERAL PESTS. | |
WO2012158437A3 (en) | Cannula apparatus and ventricular assist systems using the cannula apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |